| 0 (0%) | 09-27 09:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.95 | 1-year : | 6.95 |
| Resists | First : | 5.09 | Second : | 5.95 |
| Pivot price | 4.43 |
|||
| Supports | First : | 4.1 |
Second : | 3.49 |
| MAs | MA(5) : | 4.42 |
MA(20) : | 4.31 |
| MA(100) : | 3.52 |
MA(250) : | 3.49 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 44.7 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 5.09 | Low : | 2.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABUS ] has closed above bottom band by 46.2%. Bollinger Bands are 27% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.44 - 4.46 | 4.46 - 4.47 |
| Low: | 4.2 - 4.22 | 4.22 - 4.24 |
| Close: | 4.37 - 4.41 | 4.41 - 4.44 |
Fri, 26 Sep 2025
ABUS supplies overhead cranes to Steel Build’s new fabrication plant in UK - hoistmagazine.com
Thu, 18 Sep 2025
Best road bike helmets 2025, from entry-level to high-end - BikeRadar
Thu, 11 Sep 2025
Invesco Ltd. Has $487,000 Stake in Arbutus Biopharma Corporation $ABUS - MarketBeat
Wed, 06 Aug 2025
Abus Magomedov vs. Joe Pyfer Announced for UFC 320 - Cageside Press
Wed, 06 Aug 2025
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Thu, 10 Jul 2025
ABUS Game Changer Aero Road Helmet - Triathlete
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 192 (M) |
| Shares Float | 126 (M) |
| Held by Insiders | 21.8 (%) |
| Held by Institutions | 62.5 (%) |
| Shares Short | 10,550 (K) |
| Shares Short P.Month | 12,980 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | 0 % |
| Operating Margin | 17.8 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -52.9 % |
| Qtrly Rev. Growth | 522.2 % |
| Gross Profit (p.s.) | -0.2 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -15.21 |
| PEG Ratio | 0 |
| Price to Book value | 10.25 |
| Price to Sales | 54.82 |
| Price to Cash Flow | -14.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|